The FDA's approval to expand the trial strengthens Alpha Tau's clinical development path for Alpha DaRT in pancreatic cancer, one of the deadliest solid tumors. While no efficacy data is reported, the green light to test across both standard-of-care regimens de-risks future commercialization and supports potential broader label claims. Monitor for interim safety and response data in late 2026.
Price Chart
Executive Summary
The FDA has approved an IDE supplement expanding Alpha Tau's IMPACT pilot trial for pancreatic cancer to include 10 additional patients receiving gemcitabine/nab-paclitaxel chemotherapy, increasing total enrollment from 30 to 40. The expansion allows evaluation of Alpha DaRT in combination with both major first-line chemotherapies, broadening the potential development path for this investigational therapy in a high-unmet-need population.
Key Facts
- FDA approved an IDE supplement to expand the IMPACT trial from 30 to 40 patients
- Expansion includes 10 new patients receiving gemcitabine/nab-paclitaxel alongside Alpha DaRT
- Trial now covers both major first-line chemotherapies: mFOLFIRINOX and gemcitabine/nab-paclitaxel
- Patient recruitment now expected to complete in Q3 2026, delayed from Q2 2026
- Primary endpoints are safety, feasibility, and tolerability of Alpha DaRT implantation
Financial Impact
No direct financial impact disclosed; trial expansion may increase R&D spend modestly
Risk Factors
- Clinical trial may fail to demonstrate safety or efficacy despite regulatory allowance
- Delayed patient recruitment pushes data readout timeline into late 2026 or 2027
- Alpha Tau remains pre-revenue with history of losses and dependence on future funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3280027 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 6-K | $14.11 $15.19 | ▲ +7.65% | ▲ +7.84% | $14.77 (+4.68%) |
Aug 10, 2026 7w ago | 6-K | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | Press Release | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | 6-K | $13.60 $14.84 | ▲ +9.12% | ▲ +10.03% | $14.77 (+8.60%) |
Jul 21, 2026 10w ago | 6-K | $13.32 $14.26 | ▲ +7.06% | ▲ +4.50% | $14.77 (+10.89%) |
Jul 15, 2026 11w ago | 6-K | $12.46 $13.87 | ▲ +11.32% | ▲ +8.97% | $14.77 (+18.54%) |
Jun 23, 2026 14w ago | 6-K | $10.05 $13.01 | ▲ +29.45% | ▲ +27.52% | $14.77 (+46.97%) |
Jun 3, 2026 17w ago | Press Release | $10.58 $13.23 | ▲ +25.05% | ▲ +26.05% | $14.77 (+39.60%) |
May 11, 2026 20w ago | Press Release | $10.34 $9.19 | ▼ −11.12% | ▼ −10.82% | $14.77 (+42.84%) |
May 8, 2026 21w ago | Press Release | $8.51 $9.35 | ▲ +9.87% | ▲ +9.85% | $14.77 (+73.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access